EU Strategy on COVID-19 Therapeutics
15.9.2021
Priority question for written answer P-004242/2021
to the Commission
Rule 138
Moritz Körner (Renew)
The EU Strategy on COVID-19 Therapeutics aims to build a broad portfolio of COVID-19 therapeutics with the goal of having three new therapeutics available by October 2021 and possibly two more by the end of the year. It covers the full lifecycle of medicines from research, development, selection of promising candidates, fast regulatory approval, manufacturing and deployment to final use.
- 1.How much EU funds has the Commission allocated to support the availability of these five therapeutics?
- 2.Has the Commission taken steps to ensure that the five therapeutics are globally first (also) available in the EU, and if so, what steps?
- 3.How much of each therapeutic will be available in the EU, when, and what steps has the Commission taken to enable sufficient and immediate availability of the five therapeutics in all Member States?
Last updated: 20 September 2021